
Chu Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7797482/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sleep Deprivation Causes Behavioral, Synaptic, and Membrane Excitability Alterations in Hippocampal Neurons. Journal of Neuroscience, 2003, 23, 9687-9695.	3.6	349
2	Cyclooxygenase-2 Regulates Prostaglandin E ₂ Signaling in Hippocampal Long-Term Synaptic Plasticity. Journal of Neurophysiology, 2002, 87, 2851-2857.	1.8	277
3	Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease. Cell Reports, 2012, 2, 1329-1339.	6.4	219
4	Lipid signaling: Sleep, synaptic plasticity, and neuroprotection. Prostaglandins and Other Lipid Mediators, 2005, 77, 65-76.	1.9	174
5	Postsynaptically Synthesized Prostaglandin E2 (PGE2) Modulates Hippocampal Synaptic Transmission via a Presynaptic PGE2 EP2 Receptor. Journal of Neuroscience, 2005, 25, 9858-9870.	3.6	166
6	Homeostatic Scaling of Vesicular Glutamate and GABA Transporter Expression in Rat Neocortical Circuits. Journal of Neuroscience, 2005, 25, 7121-7133.	3.6	166
7	Δ9-THC-Caused Synaptic and Memory Impairments Are Mediated through COX-2 Signaling. Cell, 2013, 155, 1154-1165.	28.9	166
8	Cyclooxygenase-2 in Synaptic Signaling. Current Pharmaceutical Design, 2008, 14, 1443-1451.	1.9	164
9	Endogenous PGE ₂ Regulates Membrane Excitability and Synaptic Transmission in Hippocampal CA1 Pyramidal Neurons. Journal of Neurophysiology, 2005, 93, 929-941.	1.8	131
10	Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget, 2017, 8, 46691-46703.	1.8	113
11	Synaptic and Cognitive Improvements by Inhibition of 2-AG Metabolism Are through Upregulation of MicroRNA-188-3p in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2014, 34, 14919-14933.	3.6	111
12	COX-2's new role in inflammation. Nature Chemical Biology, 2010, 6, 401-402.	8.0	102
13	Endocannabinoid 2-Arachidonoylglycerol Protects Neurons by Limiting COX-2 Elevation. Journal of Biological Chemistry, 2008, 283, 22601-22611.	3.4	100
14	Inhibition of COXâ€2 expression by endocannabinoid 2â€arachidonoylglycerol is mediated via PPARâ€Î³. British Journal of Pharmacology, 2011, 163, 1533-1549.	5.4	100
15	Endocannabinoids in Synaptic Plasticity and Neuroprotection. Neuroscientist, 2015, 21, 152-168.	3.5	95
16	Altered NMDA receptor trafficking contributes to sleep deprivation-induced hippocampal synaptic and cognitive impairments. Biochemical and Biophysical Research Communications, 2006, 340, 435-440.	2.1	94
17	Lipid Signaling and Synaptic Plasticity. Neuroscientist, 2006, 12, 425-434.	3.5	84
18	PGE2glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. Journal of Physiology, 2006, 572, 735-745.	2.9	83

Сни Снем

#	Article	IF	CITATIONS
19	COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. Journal of Neurochemistry, 2007, 102, 1966-1977.	3.9	79
20	Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for <i>in vivo</i> Δ9â€THC exposureâ€impaired hippocampal synaptic plasticity. Journal of Neurochemistry, 2010, 112, 691-702.	3.9	76
21	Inhibition of Monoacylglycerol Lipase Prevents Chronic Traumatic Encephalopathy-like Neuropathology in a Mouse Model of Repetitive Mild Closed Head Injury. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 443-453.	4.3	72
22	Attenuated LTP in Hippocampal Dentate Gyrus Neurons of Mice Deficient in the PAF Receptor. Journal of Neurophysiology, 2001, 85, 384-390.	1.8	70
23	β-Amyloid increases dendritic Ca2+ influx by inhibiting the A-type K+ current in hippocampal CA1 pyramidal neurons. Biochemical and Biophysical Research Communications, 2005, 338, 1913-1919.	2.1	68
24	ZD7288 inhibits postsynaptic glutamate receptor-mediated responses at hippocampal perforant path-granule cell synapses. European Journal of Neuroscience, 2004, 19, 643-649.	2.6	66
25	Hyperpolarization-activated current (Ih) in primary auditory neurons. Hearing Research, 1997, 110, 179-190.	2.0	63
26	COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Molecular and Cellular Neurosciences, 2008, 37, 682-695.	2.2	61
27	A novel mechanism of synaptic and cognitive impairments mediated via microRNA-30b in Alzheimer's disease. EBioMedicine, 2019, 39, 409-421.	6.1	60
28	Altered hippocampal longâ€ŧerm synaptic plasticity in mice deficient in the PGE2 EP2 receptor. Journal of Neurochemistry, 2009, 108, 295-304.	3.9	54
29	Neurodevelopmental Role for VGLUT2 in Pyramidal Neuron Plasticity, Dendritic Refinement, and in Spatial Learning. Journal of Neuroscience, 2012, 32, 15886-15901.	3.6	52
30	Downâ€regulated expression of microRNAâ€338â€5p contributes to neuropathology in Alzheimer's disease. FASEB Journal, 2019, 33, 4404-4417.	0.5	46
31	Longâ€lasting potentiation of hippocampal synaptic transmission by direct cortical input is mediated via endocannabinoids. Journal of Physiology, 2012, 590, 2305-2315.	2.9	41
32	Heterogeneous expression and regulation of hippocampal prostaglandin E2 receptors. Journal of Neuroscience Research, 2005, 81, 817-826.	2.9	39
33	Endocannabinoids Differentially Modulate Synaptic Plasticity in Rat Hippocampal CA1 Pyramidal Neurons. PLoS ONE, 2010, 5, e10306.	2.5	33
34	Alleviation of Neuropathology by Inhibition of Monoacylglycerol Lipase in APP Transgenic Mice Lacking CB2 Receptors. Molecular Neurobiology, 2018, 55, 4802-4810.	4.0	29
35	Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease. Molecular Neurobiology, 2021, 58, 4122-4133.	4.0	23
36	Acetaminophen modifies hippocampal synaptic plasticity via a presynaptic 5-HT2 receptor. NeuroReport, 2003, 14, 743-747.	1.2	22

Сни Снем

#	Article	IF	CITATIONS
37	Genome-wide Gene–Asbestos Exposure Interaction Association Study Identifies a Common Susceptibility Variant on 22q13.31 Associated with Lung Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1564-1573.	2.5	21
38	TDP-43 drives synaptic and cognitive deterioration following traumatic brain injury. Acta Neuropathologica, 2022, 144, 187-210.	7.7	20
39	Enhancing endocannabinoid signalling in astrocytes promotes recovery from traumatic brain injury. Brain, 2022, 145, 179-193.	7.6	18
40	Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. Neurochemistry International, 2010, 56, 590-596.	3.8	12
41	Fine-tuning of synaptic upscaling at excitatory synapses by endocannabinoid signaling is mediated via the CB1 receptor. Scientific Reports, 2015, 5, 16257.	3.3	11
42	Homeostatic regulation of brain functions by endocannabinoid signaling. Neural Regeneration Research, 2015, 10, 691.	3.0	11
43	Long-term potentiation at hippocampal perforant path-dentate astrocyte synapses. Biochemical and Biophysical Research Communications, 2009, 383, 326-330.	2.1	10
44	Endocannabinoid Metabolism and Traumatic Brain Injury. Cells, 2021, 10, 2979.	4.1	9
45	Endocannabinoid metabolism in neurodegenerative diseases. Neuroimmunology and Neuroinflammation, 2016, 3, 268.	1.4	7
46	Endocannabinoid metabolism and Alzheimer's disease. Neural Regeneration Research, 2022, 17, 1987.	3.0	4